Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05906953 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)
A Phase 1 study of Leber Congenital Amaurosis and Inherited Retinal Diseases Caused by RPE65 Mutations, sponsored by HuidaGene Therapeutics Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT05906953: Recruiting Phase 1 study of Leber Congenital Amaurosis and Inherited Retinal Diseases Caused by RPE65 Mutations, sponsored by HuidaGene Therapeutics Co..
NCT05906953 is a Phase 1 study of Leber Congenital Amaurosis and Inherited Retinal Diseases Caused by RPE65 Mutations that is actively recruiting participants, run by HuidaGene Therapeutics Co.. The registered enrollment target is 20 participants, below the 25-participant average among 6 other Leber Congenital Amaurosis trials with a reported enrollment target (20% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05906953, a Phase 1 study of Leber Congenital Amaurosis and Inherited Retinal Diseases Caused by RPE65 Mutations, is actively recruiting participants, sponsored by HuidaGene Therapeutics Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of the study is to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutations in RPE65 gene.
Conditions Studied
Interventions
- DRUG HG004
Study Locations (3)
California
- Research Site - Sacramento
Texas
- Research Site - Houston
Shanghai Municipality
- Research Site - Shanghai
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-10-31 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What NCT05906953 shows while recruiting
NCT05906953 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 25-participant average among 6 other Leber Congenital Amaurosis trials with a reported enrollment target (20% lower).
The record links to 2 conditions, with Leber Congenital Amaurosis appearing as the primary indexed condition, and to 1 intervention - of which HG004 is the first listed.
NCT05906953 reports a single indexed study location in California, Texas, Shanghai Municipality.
Frequently Asked Questions
What is clinical trial NCT05906953 about?
NCT05906953 is a clinical study titled "Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)". The purpose of the study is to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutations in RPE65 gene.
What is the current status of trial NCT05906953?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-10-31. Estimated completion is 2025-12.
What conditions does trial NCT05906953 study?
This clinical trial studies the following conditions: Leber Congenital Amaurosis, Inherited Retinal Diseases Caused by RPE65 Mutations.
What interventions are being tested in trial NCT05906953?
The interventions under investigation include: HG004 (DRUG).
Who is sponsoring clinical trial NCT05906953?
This trial is sponsored by HuidaGene Therapeutics Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05906953 being conducted?
This trial has 3 study locations across California, Texas, Shanghai Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leber Congenital Amaurosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
ACTIVE NOT RECRUITING · Phase 1
-
Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2
ACTIVE NOT RECRUITING · Phase 1
-
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI